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Background: Improvements in the clinical condition of patients with type 2 diabetes are often accompanied by
improvements in health-related quality of life and other patient-reported outcomes (PROs), but data assessing
injectable treatment initiation from the patient’s perspective in routine clinical practice are lacking. We examined
PROs in patients initiating injectable treatment in the CHOICE (CHanges to treatment and Outcomes in patients
with type 2 diabetes initiating InjeCtablE therapy) study.
Methods: CHOICE was a 24-month, prospective observational study conducted in six European countries. Patients
initiated exenatide twice daily (BID) or insulin based on a physician’s clinical judgement. Clinical and PRO data were
collected at baseline (injectable therapy initiation) and after approximately 3, 6, 12, 18 and 24 months. The two
treatment cohorts had different baseline characteristics; therefore, no statistical comparisons of endpoints between
main cohorts were conducted.
Results: There were 2388 patients eligible for analysis (exenatide BID cohort, n = 1114; insulin cohort, n = 1274). Mean
positive changes in Impact of Weight on Quality of Life-Lite (IWQOL-Lite) total score and EuroQoL5-Dimension (EQ-5D)
index and visual analogue scale (VAS) scores were observed in both cohorts with most changes observed during the
first 6 months after injectable therapy initiation. Patients who experienced weight loss (≥1 kg) at 24 months appeared
to have higher mean improvements in IWQOL-Lite total score than did patients with weight gain or no weight change.
Patients who met the composite clinical endpoint of glycated haemoglobin (HbA1c) <7.0%, no weight gain (≤1 kg)
and no hypoglycaemia generally experienced higher mean improvements in EQ-5D index and VAS scores (compared
with patients who did not meet this endpoint) and Diabetes Health Profile-18 scores (versus the main cohorts). High
levels of missing data were observed for all PRO measures in both cohorts compared with those for clinical outcomes.
Conclusions: These data from a clinical practice study support those from clinical trials, suggesting that PROs are not
adversely affected, and may be improved, by injectable therapy initiation. PRO data may aid appropriate treatment
selection for individual patients.
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The increasing global prevalence of type 2 diabetes
(T2DM) is accompanied by increased clinical and eco-
nomic burden [1]. Achieving good metabolic control,
including tight control of blood glucose, contributes to re-
ducing the clinical, psychological, and economic burden
of T2DM, and this requires that healthcare professionals
and patients work together to achieve optimal treatment
of this chronic disease [2-5]. The influence of physical and
social factors on T2DM incidence and health outcomes is
also receiving attention [6]. Patients with T2DM require
systematic, individualised and progressive interventions
involving different therapies that address the clinical and
psychosocial aspects of their illness [2,3,6,7]. A com-
prehensive evaluation of healthcare should ascertain a
patient’s expressed health needs [7], as patient under-
standing, engagement, and commitment to the prescribed
treatment strategy is key to meeting treatment goals and
reducing morbidity and mortality associated with T2DM
[3]. A patient’s perception of how his or her condition or
treatment affects his or her quality of life is an important
consideration when making treatment decisions, and phy-
sicians should consider this information as well as clinical
data when discussing the available options with their
patients [3,8].
The health-related quality of life (HRQoL) of patients
with diabetes is often impaired, compared with a popula-
tion without diabetes, and can be affected by both clinical
and psychosocial factors [8,9]. HRQoL is inversely cor-
related with diabetes severity [5,9,10], and improvements
in the clinical condition of patients with diabetes, par-
ticularly T2DM, are often accompanied by improvements
in HRQoL and some other related patient-reported out-
comes (PROs), such as health status and psychological
well-being [8,11-14]. Newer T2DM therapies such as
glucagon-like peptide-1 (GLP-1) receptor agonists are
typically associated with weight loss; these therapies have
been associated with improvements in weight-related
quality of life (i.e. quality of life pertaining to weight) [11]
and may also demonstrate other benefits on relevant
PROs. Improvements in PROs have been reported from
several randomised clinical trials (RCTs) of exenatide
twice daily (BID) [15-17]. Although RCTs provide valuable
data regarding the efficacy of a drug in an ‘ideal’ setting,
the populations and management approach used in RCTs
may not reflect actual clinical practice, where treatment is
more complex and diverse [18]. Prospective observational
studies are therefore used to investigate effectiveness, i.e.,
how well drugs work under real world conditions subject
to several sources of variation, including patient charac-
teristics, comorbidities and concomitant medications.
Naturalistic studies such as these, conducted with less
structure than RCTs, for a longer duration of time, and
with a larger sample size, may yield different findings [17]and enhance the evidence upon which the management of
T2DM is based [3,19,20].
The aim of the analyses reported in this manuscript was
to understand the patient’s perspective following initiation
of injectable antidiabetes medication in routine clinical
practice. PROs were examined using data from the
CHOICE (CHanges to treatment and Outcomes in patients
with type 2 diabetes initiating InjeCtablE therapy) study
[21-24]. Exenatide BID and insulins were the only injectable
treatments available for T2DM when this study com-
menced. Therefore, the study recruited patients initiating
either exenatide BID or their first insulin regimen in routine
clinical practice. Baseline patient characteristics [21]
and clinical outcomes, healthcare resource use, and costs
during the 24 months after initiation of injectable therapy
in CHOICE have been reported elsewhere [22-24].
Understanding PROs following injectable therapy initi-
ation will provide additional insight from the patient’s per-
spective that, together with clinical data, will help patients
and clinicians to make better informed treatment
decisions.
Patients and methods
Study design and patients
CHOICE (www.clinicaltrials.gov identifier NCT00635492)
was a prospective, noninterventional observational
study that recruited patients from six European coun-
tries (Belgium, Denmark, France, Germany, Greece, and
Sweden) between January 2008 and October 2009. Pa-
tients aged ≥18 years and initiating their first injectable
antidiabetes therapy with exenatide BID or insulin for
T2DM in routine clinical practice were included in the
study. Patients were invited to participate in CHOICE
only after the clinical decision had been made to initiate
exenatide BID or insulin for the treatment of T2DM (in
addition to any oral antidiabetes drugs required). Treat-
ment choice (exenatide BID or insulin) was based on
the clinical judgement of the patient’s physician. Patients
gave written informed consent for the use of their data
and appropriate ethical review board approval was
obtained from the Ethics Committee of the State Medical
Association (Frankfurt, Germany), the Regional Ethical
Review Board (Stockholm, Sweden), and the Medical
Ethics Committee of University Hospitals Leuven (Leuven,
Belgium). Further details on the design of the CHOICE
study have been reported previously [21].
The primary endpoint of CHOICE was the time from
the initiation of initial injectable regimen (exenatide BID
or insulin) to significant treatment change (see Mathieu
et al. [22] for definitions). The study also aimed to des-
cribe the characteristics of patients with T2DM initiated
on injectable therapy [21], the factors associated with
changes to treatment, clinical outcomes, PROs, and the
healthcare resource use observed over 24 months.
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(initiation of injectable therapy) and at follow-up visits
when they occurred as part of clinical practice, appro-
ximately 3, 6, 12, 18, and 24 months (all ± 6 weeks) after
baseline.
Measures
PRO endpoints were measured using standardised and
validated questionnaires. Weight-related quality of life
was assessed using the Impact of Weight on Quality of
Life-Lite questionnaire (IWQOL-Lite), a 31-item scale
that assesses the domains of physical function, self-
esteem, sexual life, public distress, and work [25].
Response categories range from 1 = “never true” to
5 = “always true”. Total scores are transformed in a
linear manner to IWQOL-Lite “standardised scores”,
ranging from 0 to 100, with higher standardised scores
indicating better quality of life [26].
Health status was measured using the generic
EuroQol-5-Dimension (EQ-5D) instrument [27] [three-
level (3L) version]. In the EQ-5D, patients are asked to
report their level of functioning in five dimensions (mo-
bility, self-care, usual activities, pain/discomfort, anxiety/
depression), with each dimension assessed by one item
with three response choices (no problems, some pro-
blems, severe problems). Responses to the five items are
used to derive an overall health index score (using the UK
weighting) with a possible range from −0.594 to 1.0, where
0 represents death and 1.0 represents a perfect health state
(values below zero represent a state considered to be
“worse than death”) [28]. In addition, the EQ-5D contains
a single item visual analogue scale (VAS) on which pa-
tients rate their current health state on a scale ranging
from 0 (worst imaginable health state) to 100 (best im-
aginable health state).
HRQoL was measured using the Diabetes Health
Profile-18 instrument (DHP-18), an 18-item diabetes-
specific questionnaire with three domains: barriers to
activity, disinhibited eating, and psychological distress
[29]. Each question is scored using a 4-point Likert-type
scale ranging from 0 to 3, and subscale raw scores can
be transformed to a common score range of 0–100 with
0 representing no dysfunction.
Emotional distress was measured using the Hospital
Anxiety and Depression Scale (HADS), a 14-item ques-
tionnaire (seven items each for anxiety or depression) for
which each item is answered on a four-point scale (0–3)
[30]. Raw subscale scores for anxiety and depression are
calculated by adding all item scores together for a maxi-
mum possible score of 21. The developers provide clinic-
ally defined cut-off points to indicate whether a patient is
“within the normal range” (score of 0–7), or in a “mildly”
(8–10), “moderately” (11–14), or “severely” (15–21) dis-
ordered state.Analysis
Sample size justification
The sample size for CHOICE was based on the primary end-
point of time to first significant treatment change [21,22];
as such the study was not powered to assess changes in
PROs. Sample size was calculated using a Monte-Carlo
simulation, assuming annual patient dropout rates of 10% to
15% and a median time to significant treatment change of
9.0 months for the exenatide BID cohort and 8.6 months for
the insulin cohort [31,32]. Based on this, the study aimed to
recruit a maximum of 800 patients per country/country
group. The insulin cohort was to be larger than the exenatide
BID cohort (60% vs. 40% of patients) because of the greater
variability in the insulin cohort (linked to use of different in-
sulin regimens).Statistical analysis
All patients who provided consent to release information,
fulfilled study entry criteria, had a case report form sum-
mary page signed by an investigator and had at least one
post-baseline assessment were included in the analyses
(“eligible patients”). Due to the observational nature of
this study, patients who violated the study description or
who discontinued early from the study were included in
the analyses.
As anticipated, analysis of the baseline data indicated
that the two treatment cohorts comprised substantially
different patient populations [21]. As a consequence, stat-
istical comparisons of endpoints between the two main
cohorts were not conducted and analyses of PRO end-
points are descriptive only.
Analyses of the PRO endpoints were conducted using
available data from all eligible patients; data collected until
study discontinuation were analysed according to the co-
hort (exenatide BID or insulin) that patients were placed
in at baseline (“initiators” analysis). Item, domain, and
total scores were summarised, as relevant, using frequency
distribution and descriptive statistics. Absolute numbers
and percentages (based on the number of patients with
visits at the respective time point, as these patients had
the opportunity to provide data) were given for categorical
variables. Patients in Germany were not asked to complete
the HADS or IWQOL-Lite questionnaires (due to general
ethical concerns in Germany that patients may potentially
feel overburdened when asked to complete several ques-
tionnaires), so percentage data for these measures are
based on the number of patients with visits, excluding
those patients in Germany. Item-level missing data were
dealt with according to the instructions from the PRO
instrument developers. The potential relationship between
various clinical parameters and relevant PROs was also
examined, for example, whether IWQOL-Lite scores were
associated with weight loss or gain.
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vestigate the association of baseline characteristics with
time to achieving the clinically relevant composite end-
point of HbA1c <7.0%, no weight gain (≤1 kg), and no
hypoglycaemia [33].
Interpretation of PRO data
To assist in interpreting PRO scores, a meaningful change
in individual patient scores needs to be identified [34,35].
The proportion of patients meeting minimally important
changes (MICs) in individual PRO scores was determined
using published recommendations where available. Therefore,
a change from baseline of >0.03 on the EQ-5D index [36],
a change of >3.0 on the EQ VAS [36], and change in DHP-18
scores for barriers to activities of >5.29, disinhibited eating
of >2.80 and psychological distress of >4.87 [37] constituted a
MIC.
As there are no published MICs for the HADS (except in
patients with chronic obstructive pulmonary disease [38])
and those for the IWQOL-Lite [39] considered participants
enrolled in weight loss studies/programmes only (it was
not reported whether any participants had diabetes), the
distributions of responses to these questionnaires were cal-
culated using a cumulative distribution function (CDF).
This shows all magnitudes of change across the entire
study population and the proportion of patients at each
point along the scale score continuum who experience
change at that level or lower [40]. This allows the reader to
calculate the percentage of responders at each value of the
change score and evaluate the consistency of changes
across different response thresholds.
Results
Clinical endpoints in CHOICE
A total of 2515 patients were recruited from 322 investiga-
tor sites, mainly secondary care sites. Overall, there were
2388 eligible patients in this analysis; 1114 in the exe-
natide BID cohort and 1274 in the insulin cohort. Visit
attendance decreased over time to 873 exenatide BID
(78.4%) and 1025 insulin (80.5%) patients at the 24-month
visit. Over 24 months, 23.5% of patients discontinued the
study: lost to follow-up was the primary reason in both
cohorts (about 13.5% of each cohort), although 7.4% of
exenatide BID and 3.5% of insulin patients discontinued
due to subject decision [22].
Significant differences were observed in the baseline
patient characteristics of the exenatide BID and insulin
treatment cohorts (see Matthaei et al. [21]). Statistical
comparisons of clinical and PRO endpoints between the
two main cohorts were therefore not conducted.
A total of 470 patients from the exenatide BID cohort
(42.2%) and 459 patients from the insulin cohort (36.0%)
had a significant treatment change [22] during the study.
In the exenatide BID cohort, 74.3% of the first significanttreatment changes were discontinuations of initial injec-
table therapy, with the rest comprising the addition of oral
or injectable antidiabetes medication to their exenatide
BID regimen. Overall, the most common first significant
treatment change for insulin patients was the addition of a
new oral or injectable medication (58.2% of first signi-
ficant treatment changes). Discontinuations of ≥1 insulin
initiated at baseline accounted for 24.2% of the first
significant treatment changes for patients in the insulin
cohort.
During the study, 393 patients in the exenatide BID
cohort (35.3%) and 155 patients in the insulin cohort
(12.2%) discontinued their initial injectable therapy. The
most common reason for such discontinuation in both
cohorts was inadequate response [170 patients in the exe-
natide BID cohort (15.3%) and 87 patients in the insulin
cohort (6.8%)]. Adverse events were cited as the reason
for treatment discontinuation for 91 patients in the exe-
natide BID cohort (8.2%) and 11 patients in the insulin
cohort (0.9%) [22].
Table 1 presents the main clinical data at baseline and
24 months and a full description of the clinical data has
been reported previously [22]. Glycaemic control im-
proved in both the exenatide BID and insulin cohorts. A
mean weight loss was seen in the exenatide BID cohort,
whereas a mean weight gain was seen in the insulin
cohort. Gastrointestinal (GI) events were experienced by
30.8% of the exenatide BID cohort and 5.3% of the in-
sulin cohort. The proportion of exenatide BID patients
with GI events was higher in the first 6 months of the
study (26.2% of patients with data) than in subsequent
6-month periods (<8% of patients with data).
Patient-reported outcomes
Table 2 summarises the baseline PRO scores for patients
in the exenatide BID and insulin cohorts. High levels of
missing data and large standard deviations (SDs) were
noted for all PRO measures in both cohorts.
IWQOL-Lite
There was a mean positive change in overall IWQOL-
Lite total score from baseline in both treatment cohorts
during the first 6 months after initiation of injectable
therapy (Figure 1a). Thereafter scores tended to plateau
in the exenatide BID cohort and decrease in the insulin
cohort, remaining above baseline levels throughout the
24-month study. When weight change (≥1 kg in either
direction) at 24 months was considered, mean (SD)
baseline IWQOL-Lite scores for patients who later had
weight change (compared with baseline) at 24 months
were: exenatide BID, weight loss 75.51 (19.64); weight
gain 79.17 (18.63); no weight change 80.48 (18.00); insu-
lin: weight loss 81.17 (19.41); weight gain 85.09 (16.57);
no weight change 85.81 (17.42). Mean (SD) changes in
Table 1 Baseline characteristics and 24-month clinical outcomes: patients initiated on exenatide twice daily (BID) or insulin
Variable Exenatide BID Insulin
Baseline Baseline
(N = 1114)a (N = 1274)a
Male, n (%) n = 1114 n = 1274
598 (53.7) 733 (57.5)
Age, years n = 1114 n = 1274
58.1 (10.1) 63.7 (10.9)
Time since diabetes diagnosis, years n = 1105 n = 1263
8.2 (5.7) 9.8 (7.3)
Diabetes complications, n (%) n = 1114 n = 1274
≥1 macrovascular complication 200 (18.0) 320 (25.1)
≥1 microvascular complication 164 (14.7) 263 (20.6)
Baseline 24 months Baseline 24 months
(N = 1114)a (N = 873)a (N = 1274)a (N = 1025)a
Weight, kg n = 1112 n = 810 n = 1270 n = 947
101.2 (21.7) 98.3 (21.3) 84.2 (17.6) 86.7 (17.8)
BMI, kg/m2 n = 1100 n = 805 n = 1265 n = 942
35.3 (6.6) 34.2 (6.4) 29.7 (5.4) 30.6 (5.5)
Blood pressure, mmHg n = 1103 n = 769 n = 1259 n = 895
Systolic 137.7 (16.5) 134.8 (15.2) 137.4 (17.4) 133.9 (15.3)
Diastolic 81.7 (9.6) 78.7 (9.7) 80.2 (9.9) 78.0 (8.8)
HbA1c,% n = 1087 n = 812 n = 1245 n = 944
8.4 (1.4)b 7.3 (1.2) 9.2 (1.9)b 7.3 (1.1)
Patients with HbA1c <7%, n (%) n = 1087 n = 705 n = 1245 n = 871
128 (11.8) 258 (36.6)c 75 (6.0) 333 (38.2)c
No. of OADs used, n (%) n = 1114 n = 873 n = 1274 n = 1025
0 76 (6.8) 94 (10.8) 333 (26.1) 304 (29.7)
1 499 (44.8) 375 (43.0) 574 (45.1) 473 (46.1)
2 491 (44.1) 341 (39.1) 341 (26.8) 220 (21.5)
≥3 48 (4.3) 63 (7.2) 26 (2.0) 28 (2.7)
Patients with ≥1 hypoglycaemic event, n (%)d n = 1112 n = 1061 n = 1274 n = 1221
59 (5.3) 195 (18.4) 56 (4.4) 449 (36.8)
Patients with ≥1 GI symptom, n (%) n = 1113 n = 1060 n = 1273 n = 1219
72 (6.5) 327 (30.8)e 47 (3.7) 64 (5.3)e
Patients achieving lipid targets, n (%)
HDL-C >50 mg/dl n = 989 n = 651 n = 1083 n = 737
287 (29.0) 234 (35.9) 336 (31.0) 278 (37.7)
LDL-C <100 mg/dl n = 967 n = 635 n = 1055 n = 729
420 (43.4) 292 (46.0) 384 (36.4) 307 (42.1)
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Table 1 Baseline characteristics and 24-month clinical outcomes: patients initiated on exenatide twice daily (BID) or insulin
(Continued)
Triglycerides <150 mg/dl n = 1005 n = 659 n = 1118 n = 753
362 (36.0) 326 (49.5) 450 (40.3) 417 (55.4)
HDL-C >50, LDL-C <100 & Triglycerides <150 mg/dl n = 1012 n = 659 n = 1113 n = 748
73 (7.2) 81 (12.3) 75 (6.7) 82 (11.0)
Continuous data are means (SD).
BID = twice daily; BMI = body mass index; HbA1c = glycated haemoglobin; OAD = oral antidiabetes drug; GI = gastrointestinal; HDL-C = high-density lipoprotein
cholesterol; LDL-C = low-density lipoprotein cholesterol; SD = standard deviation.
aN numbers represent the number of patients who attended a baseline or 24-month visit. Percentages are based on the number of patients with data.
bMost recent in previous 3 months.
cData from the subgroup of 959 patients in the exenatide BID initiators group and 1170 patients in the insulin initiators group with baseline HbA1c ≥7.0% at
baseline (254 and 299 patients, respectively, had missing data).
dPatient recall: baseline = past 3 months; 24 months = patients recalled events at each visit (between baseline and 24 months) that they had experienced since
their previous visit.
ePatient recall: Baseline = past 4 weeks; 24 months = patients recalled symptoms at each visit (between baseline and 24 months) that they had experienced since
their previous visit.
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baseline to 24 months in the exenatide BID cohort were:
weight loss +4.36 (13.90), weight gain −0.13 (12.34), no
weight change +1.18 (13.32). Respective change values for
the insulin cohort were: +2.98 (13.16), –0.04 (11.57), +1.61
(11.01).
The CDF for the IWQOL-Lite total score (Figure 2)
showed that 57.7% of exenatide BID and 53.0% of insulin
patients reported no worsening in IWQOL-Lite scores
at the 24-month visit (missing data overall: 13.6%).
EQ-5D
The proportions of patients with visits (in both cohorts)
who reported at least some problems with the single
domains “mobility”, “self-care” and “usual activities” of the
EQ-5D generally showed little change over the 24 months
of the study (data not shown), although the percentage of
patients overall with missing data for EQ-5D single
domains increased from ~2% at baseline to ~12% at the
24-month visit. However, the proportions of patients
reporting at least some problems with “pain/discomfort”
were 52.8% at baseline and 43.4% at 24 months in the exe-
natide BID cohort and 53.3% at baseline and 47.4% at
24 months in the insulin cohort. The proportions of pa-
tients who reported at least some problems with “anxiety/
depression” were 46.9% at baseline and 35.4% at 24 months
in the exenatide BID cohort; respective values were 47.6%
and 35.9% in the insulin cohort.
The greatest mean improvements in the EQ-5D index
score were observed between baseline and 6 months for
both cohorts (Figure 1b). Mean changes were above
MIC for the exenatide BID cohort at all time points, and
were above MIC only at 6 months in the insulin cohort;
between baseline and 24 months, 32.0% of patients in
the exenatide BID cohort and 27.3% of patients in the
insulin cohort had improved EQ-5D index scores by
more than the MIC (Table 3). Similarly, both cohorts ex-
perienced a mean increase in the EQ-VAS score over24 months, with most change occurring between baseline
and 6 months (Figure 1c). Mean changes in EQ-VAS
scores were above the MIC at all time points for both
cohorts; EQ-VAS scores had improved by more than the
MIC for 47.4% of patients in the exenatide BID cohort
and 44.7% of patients in the insulin cohort at 24 months
(Table 3). Post hoc multivariate Cox regression models
showed that baseline EQ-5D index values (VAS scores
were not evaluated) were not significantly associated with
time to achieving the composite endpoint proposed by
Zinman et al. [33]. However, patients in both the exe-
natide BID and insulin cohorts who met the composite
endpoint (n = 271 in the exenatide BID cohort, n = 144
in the insulin cohort) experienced numerically greater
changes in mean (SD) EQ-5D index and VAS score after
24 months [exenatide BID: index: +0.08 (0.23), VAS: +9.01
(18.24); insulin: index: +0.02 (0.32), VAS: +7.57 (21.78)]
than the respective group of patients who did not meet
the composite endpoint [exenatide BID: index: +0.04
(0.24), VAS: +6.69 (16.69); insulin: index: +0.01 (0.26),
VAS: +4.63 (16.95)].
DHP-18
Changes in DHP-18 scores over the 24-month study are
presented in Figure 1d. Most changes were small and
below their respective MIC, except for change in disinhi-
bited eating at all time points for the exenatide BID co-
hort. The number of patients whose DHP-18 scores
improved or worsened by more than the MIC at the
24-month visit is shown in Table 3.
In both cohorts, patients who met the composite end-
point had numerically lower (better) mean baseline scores
compared with their respective total cohort for all DHP-18
parameters (data not shown; baseline scores for the total
cohort are presented in Table 2). Patients who met the
composite endpoint also generally experienced numeri-
cally greater DHP-18 score improvements over 24 months
than those in the main cohort. The differences in DHP-18
Table 2 Patient-reported outcome (PRO) scores at baseline
PRO Exenatide BID Insulin
N = 1114a N = 1274a
IWQOL-Lite*
Total score n = 715 n = 817
77.25 (19.41) 84.49 (17.37)
Subscales n = 648–707b n = 725–812b
Physical function 69.35 (23.68) 77.84 (21.03)
Self-esteem 76.31 (26.68) 86.47 (21.41)
Sexual life 76.25 (28.50) 82.54 (26.81)
Public distress 89.25 (18.77) 93.60 (15.51)
Work 85.50 (20.15) 90.25 (18.09)
EQ-5D
Index score** n = 1079 n = 1242
0.73 (0.27) 0.71 (0.27)
Subscales n = 1086–1090 n = 1249–1254
Number (%)c of patients who reported at least some problems with:
Mobility 322 (28.9) 442 (34.7)
Self-care 76 (6.8) 125 (9.8)
Usual activities 232 (20.8) 301 (23.6)
Pain/discomfort 588 (52.8) 679 (53.3)
Anxiety/depression 523 (46.9) 607 (47.6)
VAS score++ n = 1063 n = 1225
64.63 (17.94) 63.77 (19.13)
DHP-18***
Barriers to activity n = 1090 n = 1251
30.95 (21.41) 29.45 (19.41)
Disinhibited eating n = 1089 n = 1253
45.88 (21.75) 38.35 (21.65)
Psychological distress n = 1086 n = 1245
29.18 (21.34) 26.53 (21.07)
HADS+ anxiety n = 692 n = 794
6.38 (4.40) 6.96 (4.59)
HADS+ depression n = 695 n = 787
5.44 (4.09) 6.04 (4.35)
Data are presented as mean (SD), unless otherwise stated.
PRO = patient-reported outcome; BID = twice daily, IWQOL-Lite = Impact of Weight on Quality of Life-Lite, EQ-5D = EuroQoL-5D, VAS = visual analogue scale,
DHP-18 = Diabetes Health Profile-18, HADS = Hospital Anxiety and Depression Scale.
aN represents the number of patients who attended a baseline visit. Percentages are based on N. The number of patients with data for each endpoint or group of
endpoints (n) is presented above that endpoint or group of endpoints.
bFor both cohorts, the lowest n number for the IWQOL-Lite subscales was for data for the sexual life subscale, the highest n number was for the physical
function subscale.
cPercentages are based on the number of patients who attended the baseline visit.
*IWQOL-Lite standardised scores, range 0–100. Higher scores indicate higher quality of life. As IWQOL-Lite was not applied in Germany, the numbers of patients
who attended a baseline visit and had the opportunity to provide IWQOL-Lite data were 730 (exenatide BID cohort) and 836 (insulin cohort).
**U.K.-specific coefficients and country-specific coefficients were used where available. Higher scores indicate better health status.
++Range 0–100. Higher scores indicate better health status.
***Standardised scores for subscales, range 0–100. Lower scores indicate better health-related quality of life.
+Raw scores for subscales, range 0–21. Lower scores indicate lower levels of emotional distress. As HADS Anxiety and Depression were not applied in Germany,
the number of patients who attended a baseline visit and had the opportunity to provide HADS data were 730 (exenatide BID cohort) and 836 (insulin cohort).
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Figure 1 Changes in patient-reported outcomes (PROs) over 24 months in the CHOICE study. Changes from baseline in PRO measures
over 24 months after initiation of exenatide twice daily (BID) or insulin are presented. The number of patients with change data at each time
point is presented below the time point. a) Mean change in standardised Impact of Weight on Quality of Life-Lite (IWQOL-Lite) total score.
b) Mean change in EuroQoL-5-Dimension (EQ-5D) index score. c) Mean change in EuroQoL-visual analogue scale (EQ-VAS) score. d) Mean
changes in standardised Diabetes Health Profile-18 (DHP-18) scores. e) Mean change in Hospital Anxiety and Depression Scale (HADS) scores.
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endpoint and the main cohorts were generally lower than
the MIC, with the exception of disinhibited eating at
24 months in the exenatide BID cohort (data not shown).HADS anxiety and depression
Changes in HADS anxiety and depression scores are
presented in Figure 1e.
At baseline, 59.2% of exenatide BID and 53.8% of insulin
patients had responses “within the normal range” for an-
xiety. Responses in the “mildly”, “moderately” or “severely”
disordered states were given by 18.2%, 13.2% and 4.2% of
exenatide BID patients and 20.8%, 14.6%, and 5.7% of
insulin patients, respectively. For depression, 66.2% of exe-
natide BID and 60.6% insulin patients had responses
“within the normal range”. Responses in the “mildly”,
“moderately” or “severely” disordered states were given by
16.3%, 10.0% and 2.7% of exenatide BID patients and
17.9%, 11.8% and 3.7% of insulin patients. The proportion
of patients with responses within the normal range and in
each disordered state generally decreased over the course
of the study (data not shown), but changes were small andChanges in IWQOL-LiteSta
Figure 2 CDF of IWQoL-Lite questionnaire total score change from ba
IWQOL-Lite = Impact of Weight on Quality of Life-Lite Higher scores indicatthe amount of missing data increased (overall: anxiety
5.1% at baseline, 16.0% at 24 months; depression 5.4% at
baseline, 17.4% at 24 months).
The CDFs for the HADS anxiety and depression scores
(Figures 3a and b) indicate that 52.6% and 50.3% of exena-
tide BID patients and 52.9% and 48.0% of insulin patients
reported no worsening in HADS anxiety and depression
scores, respectively, at the 24-month visit (missing data
overall: anxiety 19.6%; depression 21.5%).Discussion
The initiation of injectable therapy may represent an im-
portant milestone for the patient from both a clinical
and personal point of view: in addition to the knowledge
that their condition has progressed to requiring inject-
able therapy, the patient may be fearful of injections and
side effects. CHOICE measured PROs at, and during the
24 months following, initiation of injectable therapy with
exenatide BID or insulin. The data suggest that initiation
of injectable therapy with either exenatide BID or insulin
does not adversely affect weight-related quality of life,
health status, HRQoL, or emotional distress, and mayndardised Score from baseline to 24 months
seline to 24 months. CDF = cumulative distribution function;
e higher quality of life. IWQOL-Lite was not applied in Germany.
Table 3 Patients with a change in PROs greater than the
MIC from baseline to 24 months
PRO Exenatide BID Insulin
(N = 873)* (N = 1025)*
EQ-5D index score n = 739 n = 893
n (%) improving by > MIC (0.03) 279 (32.0) 280 (27.3)
n (%) worsening by >MIC (0.03) 194 (22.2) 288 (28.1)
EQ-5D VAS score n = 716 n = 868
n (%) improving by > MIC (3.0) 414 (47.4) 458 (44.7)
n (%) worsening by >MIC (3.0) 150 (17.2) 224 (21.9)
DHP-18 (standardised scores)
Barriers to activity n = 736 n = 896
n (%) improving by > MIC (5.29) 231 (26.5) 251 (24.5)
n (%) worsening by >MIC (5.29) 174 (19.9) 250 (24.4)
Disinhibited eating n = 741 n = 899
n (%) improving by > MIC (2.80) 364 (41.7) 415 (40.5)
n (%) worsening by >MIC (2.80) 247 (28.3) 308 (30.0)
Psychological distress n = 731 n = 890
n (%) improving by > MIC (4.87) 306 (35.1) 365 (35.6)
n (%) worsening by >MIC (4.87) 254 (29.1) 311 (30.3)
PRO = patient-reported outcome; MIC, minimally important change; BID = twice
daily, EQ-5D = EuroQoL-5D, VAS = visual analogue scale, DHP-18 = Diabetes
Health Profile-18.
*N numbers represent the number of patients who attended a 24-month visit.
Percentages are based on N. The number of patients with data for each
endpoint (n) is presented above each endpoint.
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measures. These PRO data support those from previous
clinical trials [15-17] and help address an identified need
for long-term prospective data to understand whether
PRO benefits observed in trials of incretin therapy are
realised in clinical practice [11]. Analysis of PRO data
from the CHOICE study supports injectable therapy ini-
tiation, suggesting that, from the patients’ perspective,
the disutility associated with daily injections [41,42] is
offset by the clinical improvements observed. Consistent
with clinical variables [22], most change in PRO mea-
sures was seen in the first 6 months.
Heavier body weight has been associated with disutility
in patients with T2DM, and lower body weight with added
utility [41]. In CHOICE, patients who later achieved
weight loss (≥1 kg) appeared to have poorer weight-
related quality of life at baseline (i.e. before injectable
therapy initiation), compared with those who experienced
either no weight change or weight gain, suggesting that
poor weight-related quality of life could improve moti-
vation to lose weight. As expected, weight-related quality
of life then appeared to be affected by whether or not
patients gained or lost weight (≥1 kg): those who ex-
perienced weight loss appeared to have higher mean
IWQOL-Lite score changes than those with no weightchange or weight gain, indicating an improvement in
weight-related quality of life as well as the clinical bene-
fits of weight loss for these patients. However, although
patients in the exenatide BID cohort experienced a
mean weight loss and those in the insulin cohort expe-
rienced a mean weight gain, an overall mean increase in
IWQOL-Lite score was observed for both cohorts du-
ring the study. The improvement in IWQOL-Lite score
following the initiation of exenatide BID in CHOICE is
in agreement with 12-month results from the U.S. exe-
natide BID observational study (ExOS) [43].
EQ-5D index and VAS scores generally improved
throughout the CHOICE study. These changes are encou-
raging, given that patients with T2DM in the longitudinal
US Study to Help Improve Early evaluation and manage-
ment of risk factors Leading to Diabetes (SHIELD) had a
significantly greater decline in EQ-5D index scores over
5 years, compared with people without diabetes, and this
decline was greater in patients with T2DM complications
than in those without complications [44]. The proportion
of patients in both cohorts of the CHOICE study repor-
ting at least some problems with “anxiety/depression” nu-
merically decreased over 24 months according to EQ-5D,
and small mean improvements were observed in anxiety
and depression according to the HADS. However, both
these observations were confounded by increasing propor-
tions of missing data from baseline to 24 months. At the
24-month visit, around half of patients in both cohorts re-
ported no worsening in HADS anxiety and depression
scores, although around 20% of patients had missing data
for this analysis. Depression is a recognised problem in pa-
tients with T2DM [45], and both EQ-5D and HADS data
may be important in monitoring this issue. EQ-5D data
are required by reimbursement agencies to make decisions
but HADS may be more relevant to clinical practice.
Although post hoc analyses revealed that baseline EQ-5D
index score (VAS was not included in these analyses) was
not significantly associated with time to achieving the
composite clinical endpoint (HbA1c <7.0%, no weight
gain (≤1 kg), and no hypoglycaemia [33]), greater mean
changes in EQ-5D index and VAS scores were observed
for patients in both cohorts who met this composite end-
point during the study than for those who did not meet
this endpoint. This suggests that achievement of meaning-
ful clinical improvement (following injectable treatment
initiation) may result in improved health status and that
better health status at baseline may not influence the like-
lihood of patients later achieving meaningful clinical
improvement.
All of the previously discussed PROs are generic and are
used across a range of clinical conditions. Generic instru-
ments include items that may be irrelevant and/or do not
specifically enhance our understanding of the impact of
diabetes, and they exclude domains that are likely to be of
Changes in Anxiety Score from baseline to 24 months
Changes in Depression Score from baseline to 24 months
a
b
Figure 3 CDF of HADS score change from baseline to 24 months. a) CDF for HADS anxiety score change from baseline. b) CDF for HADS
depression score change from baseline to 24 months. CDF = cumulative distribution function; HADS = Hospital Anxiety and Depression Scale
Lower scores indicate lower levels of emotional distress. HADS Anxiety and Depression were not applied in Germany.
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allow comparison with other conditions, but they are
likely to be “more sensitive to change and responsive to
subgroup differences than a generic instrument” [47]. The
DHP-18 is a diabetes-specific PRO measure and was used
to examine the potential impact of injectable therapy
initiation on diabetes-related HRQoL. Most changes in
DHP-18 scores were below the relevant MICs, with the
exception of improved disinhibited eating at all time
points for the exenatide BID cohort. This improvement
was achieved after 6 months and maintained throughout
the study. It is interesting that the main improvement in
disinhibited eating in the exenatide BID cohort wasobserved during the first 6 months. Although the pro-
portion of exenatide BID patients experiencing GI events
decreased as the study progressed, these data suggest that
the improvement in disinhibited eating was not com-
pletely offset by GI events. Patients who met the com-
posite clinical endpoint appeared to have higher DHP-18
score changes over 24 months than was observed in the
total cohort.
These data add to a growing body of clinical evidence
regarding the initiation of injectable therapies in patients
with T2DM in routine clinical practice, by considering
its potential impact on PROs. However, high levels of
missing data were observed for PRO measures
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clinical outcomes [22]. There are a number of potential
explanations for this. For example, PROs require the pa-
tient to complete questionnaires, and this may be burden-
some to the patient [48], or considered as interventional
or less important than obtaining clinical information if
time is constrained. Indeed, two of the PRO question-
naires used in this study were not applied in Germany due
to concerns about patient burden. This ethical constraint
may have resulted in patients in Germany having a per-
ceived lighter participation burden compared with pa-
tients in other countries. Patients may also be reluctant to
answer certain questions that they consider to be too per-
sonal, especially if the setting lacks privacy. Indeed, for the
IWQOL-Lite subscales in CHOICE, missing data were
highest for the sexual life subscale. Additionally, the high
level of missing data may itself be of significance. As pa-
tients generally comply with requirements for clinical data
(e.g., give blood samples as requested), there is more
scope for patients to choose whether or not to answer
particular questions in questionnaires, and this may lead
to a self-selection bias. For example, patients with a par-
ticularly high or low HRQoL may be more compelled to
complete questionnaires.
In addition to the general limitations associated with
prospective observational studies, this study has some fur-
ther limitations. As physicians in routine practice likely
chose exenatide BID or insulin based on different patient
characteristics, the data for the two cohorts cannot be
directly compared or attributed to either treatment, and
no statistical comparisons of the cohorts were therefore
performed. The analyses in CHOICE were based on an
“initiators” analysis, in which patients remained in the
cohort they were placed in at baseline regardless of
whether or not they changed treatment, and no adjust-
ment of PRO data for such changes was made. PROs may
also be affected over time by cognitive reframing, a natural
fluctuation that can result in changes in patients’ percep-
tions of baseline feelings that can influence their percep-
tion of an acceptable quality of life. Additionally, social
and cultural factors were not considered in this analysis.
Conclusions
These data from the 24-month CHOICE study support
those from other studies suggesting that PROs are not ad-
versely affected, and may be improved, by the initiation of
injectable therapy. As patients are taking a more active
role in treatment decisions [3], and as the patient’s percep-
tion of the effects of their treatment on their quality of life
may affect adherence, and therefore clinical effectiveness,
PRO data can help the clinician to select the most appro-
priate treatment for individual patients. We believe that
data such as ours enable better understanding of the
psychological, as well as clinical, aspects associated withtreatment selection in routine clinical practice and will be-
come of increasing importance in shared clinical decision-
making. Further research is needed to better understand
psychosocial aspects that affect how patients value health
and treatments [13] and to identify the most important
PRO measures from an economic point of view, as well as
those most associated with clinical improvements [49].
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